Place · Level 3 · Supplement
NMN / NR — NAD⁺ precursors
抗衰营销最响的赛道 · 池子下降 ≠ 前体不足 · CD38 才是凶手 · 人体硬终点 0 个
Last updated
Story path
Chapter 1
NAD⁺ + 3 precursors
NAD⁺ + 3 precursors
nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. (nicotinamide adenine dinucleotide) is one of the busiest 'electron carriers' in cell metabolism. It accepts electrons in the ETC to become NADH (covered in niacin-b3/nad earlier), but NAD⁺ has a second role: enzyme-reaction substrate — once cleaved, it's gone and must be re-synthesized.
The body makes NAD⁺ via three main pathways:
De novo synthesis: tryptophan → quinolinic acid → NAD⁺ (slow, energy-expensive)Preiss-Handler: niacin (NA) → NaMN → NAD⁺ (the old drug niacin goes this way)Salvage: nicotinamide → NMN → NAD⁺ (NMN is the key intermediate of this path; NR is the stable precursor of NMN)
Relationship between NMN, NR, and NA:
NA (niacin) — FDA-approved lipid-lowering drug since 1955, 2–3 g large doses, real flushing / liver toxicity side effects but A-level evidenceNR (nicotinamide riboside) — Tru Niagen / Niagen, commercialized 2013, 200–1000 mg/dayNMN (nicotinamide mononucleotide) — Renue / Wonderfeel / various influencer brands, 250–1000 mg/day
All three eventually converge on the same NAD⁺ pool. But niacin runs $8/month while NMN runs $60–90/month — and that gap is one of the core stories to compare here.
The body makes NAD⁺ via three main pathways:
De novo synthesis: tryptophan → quinolinic acid → NAD⁺ (slow, energy-expensive)Preiss-Handler: niacin (NA) → NaMN → NAD⁺ (the old drug niacin goes this way)Salvage: nicotinamide → NMN → NAD⁺ (NMN is the key intermediate of this path; NR is the stable precursor of NMN)
Relationship between NMN, NR, and NA:
NA (niacin) — FDA-approved lipid-lowering drug since 1955, 2–3 g large doses, real flushing / liver toxicity side effects but A-level evidenceNR (nicotinamide riboside) — Tru Niagen / Niagen, commercialized 2013, 200–1000 mg/dayNMN (nicotinamide mononucleotide) — Renue / Wonderfeel / various influencer brands, 250–1000 mg/day
All three eventually converge on the same NAD⁺ pool. But niacin runs $8/month while NMN runs $60–90/month — and that gap is one of the core stories to compare here.
Why NAD⁺ falls with age
Massudi 2012 / Camacho-Pereira 2016 and others observed: in multiple human tissues, nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. falls about 50% from youth to old age. This is the starting point of the entire 'anti-aging NAD⁺ supplementation' market.But why it falls — the key isn't insufficient precursor:
Elderly people's dietary niacin / tryptophan don't suddenly run shortSalvage pathway enzyme activity doesn't drop obviously eitherWhat really rises is the consumption end — three downstream enzymes are eating NAD⁺:
1. Sirtuins (SIRT1-7) — the longevity gene family, 'restrained consumers'
2. PARP1/2 — emergency mobilizers for DNA damage
3. CD38 — age-related NADase, the main consumer, with expression / activity rising ~2-3× in old tissues (Camacho-Pereira 2016 *Cell Metab*, consistent across adipose, liver, muscle, and spleen)
Like 'pool water level dropping': it's not that the faucet slowed, it's that the drain at the bottom got bigger.
So: direct precursor supplementation can short-term raise the pool (Martens 2018: NR 1000 mg/day × 6 weeks raised blood NAD⁺ +60%), but as long as the consumption end is unchanged, within days to weeks the water level re-equilibrates — this logic is unpacked in detail in the next scene and L4.
三种货 · 都通向同一个池子
先把来路说全。除了正文里那条救援线, 身体还有两条更绕的备用路: 一条从色氨酸慢慢新造 (de novo), 一条从烟酸经 NaMN 拼起来, 也就是老药 niacin 走的 Preiss-Handler 路。三条路最后通向的是同一个 nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. 池子——这一点是后面所有价格比较的前提: 终点相同, 差的只是入口、价钱和证据。NA (niacin, 烟酸) — FDA 1955 年批的降脂药, 2-3 g 大剂量, 流脸、肝毒副作用真实, 但证据 A 级, 一个月约 8 美元NR (nicotinamide riboside) — Tru Niagen / Niagen, 2013 商业化, 200-1000 mg/天NMN (nicotinamide mononucleotide) — Renue / Wonderfeel / 各种网红牌, 250-1000 mg/天, 一个月 60-90 美元
换句话说, 你在货架上看到的价差, 买到的不是更高的终点, 只是不同的入口。哪个入口更划算, 要等看完消耗端和临床证据两幕才答得了——决策表在最后一幕。
Chapter 2
NAD⁺ consumers
NAD⁺ consumers
If you remember one thing about NMN/NR, remember this: the bottleneck of the nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. pool decline isn't precursors, it's consumers. Three enzymes are eating NAD⁺:
1. Sirtuins (SIRT1-7) — restrained type
Deacetylases; each acetyl group removed consumes one NAD⁺ → producing nicotinamide + 2'-O-acetyl-ADP-riboseThe longevity gene family (Sinclair lab favorite)Km is high ~150–200 µM, meaning they're sensitive to NAD⁺ concentration but not 'hungry'Restrained consumption — this is the basis of the 'supplement NAD⁺ → activate SIRT → extend lifespan' hypothesis
2. PARP1/2 — emergency gluttons
During DNA single- or double-strand breaks, PARP cleaves large amounts of NAD⁺ → attaching ADP-ribose chains to proteins at damage sites (PARylation)Each PARylation event consumes dozens to hundreds of NAD⁺, acute consumption rate 10–100 × SirtuinsUV light, oxidative stress, and chronic inflammation all continuously trigger thisElderly people accumulate more DNA damage → PARP works continuously → NAD⁺ is continuously burned
3. CD38 — the main age-related culprit
NAD glycohydrolase, cleaves NAD⁺ in one cut → nicotinamide + cyclic ADP-ribose (cADPR, a calcium-signaling molecule)CD38 expression rises with age; in old tissues its activity rises ~2-3× (Camacho-Pereira 2016 *Cell Metab*; consistent across adipose, liver, muscle, and spleen)The main explanation for age-related NAD⁺ decline — not precursor insufficiencyCD38 inhibitors (78c, apigenin, etc.) are a separate anti-aging research direction
Key insight: supplementing precursors raises inflow; CD38 is an enlarged drain. Without fixing both ends, the pool stays low.
Click 'Take a closer look at this scene →' for the 4-step animation.
1. Sirtuins (SIRT1-7) — restrained type
Deacetylases; each acetyl group removed consumes one NAD⁺ → producing nicotinamide + 2'-O-acetyl-ADP-riboseThe longevity gene family (Sinclair lab favorite)Km is high ~150–200 µM, meaning they're sensitive to NAD⁺ concentration but not 'hungry'Restrained consumption — this is the basis of the 'supplement NAD⁺ → activate SIRT → extend lifespan' hypothesis
2. PARP1/2 — emergency gluttons
During DNA single- or double-strand breaks, PARP cleaves large amounts of NAD⁺ → attaching ADP-ribose chains to proteins at damage sites (PARylation)Each PARylation event consumes dozens to hundreds of NAD⁺, acute consumption rate 10–100 × SirtuinsUV light, oxidative stress, and chronic inflammation all continuously trigger thisElderly people accumulate more DNA damage → PARP works continuously → NAD⁺ is continuously burned
3. CD38 — the main age-related culprit
NAD glycohydrolase, cleaves NAD⁺ in one cut → nicotinamide + cyclic ADP-ribose (cADPR, a calcium-signaling molecule)CD38 expression rises with age; in old tissues its activity rises ~2-3× (Camacho-Pereira 2016 *Cell Metab*; consistent across adipose, liver, muscle, and spleen)The main explanation for age-related NAD⁺ decline — not precursor insufficiencyCD38 inhibitors (78c, apigenin, etc.) are a separate anti-aging research direction
Key insight: supplementing precursors raises inflow; CD38 is an enlarged drain. Without fixing both ends, the pool stays low.
Click 'Take a closer look at this scene →' for the 4-step animation.
三个消耗者 · 规格与证据
缸边上那三样东西, 学名和规格是这样的。nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. 池下降的瓶颈不在前体, 在消耗者——下面每一条都是这句话的注脚。1. Sirtuins (SIRT1-7) — 节制型
去乙酰化酶, 每去掉一个乙酰基消耗一个 NAD⁺ → 产生 nicotinamide + 2'-O-acetyl-ADP-ribose长寿基因家族 (Sinclair 实验室的最爱)Km 高 ~150-200 µM, 意味着对 NAD⁺ 浓度敏感, 不饥渴节制式消耗——这是补 NAD⁺ → 激活 SIRT → 延寿假说的基础
2. PARP1/2 — 紧急狂吃型
DNA 单链/双链断裂时, PARP 大量切 NAD⁺ → 把 ADP-ribose 链装到损伤位置的蛋白上 (PARylation)每个 PARylation 事件吃掉数十到数百个 NAD⁺, 急性消耗速率 10-100 × Sirtuin紫外线、氧化应激、慢性炎症都会持续触发老年人 DNA 损伤增多 → PARP 持续工作 → NAD⁺ 持续被烧
3. CD38 — 年龄相关主要凶手
NAD glycohydrolase, 一刀切 NAD⁺ → nicotinamide + cyclic ADP-ribose (cADPR, 钙信号小分子)CD38 表达量随年龄上升; 老年组织里活性约 2-3 倍 (Camacho-Pereira 2016 Cell Metab; 跨脂肪、肝 / 肌肉、脾一致)是老年 NAD⁺ 下降的主要解释, 不是前体不足CD38 抑制剂 (78c, apigenin 等) 是一个独立的抗衰研究方向
把三条并起来看就清楚了: 前两个的活跃度主要跟着你干了什么 (有没有活要干、有没有损伤要修) 走, 第三个跟着年龄走。所以年龄这个变量真正推动的是 CD38 那一路, 而市面上所有补剂动的都是入水那一端。
Precursor + CD38 inhibitor stack
If the logic above is right, the truly potentially effective anti-aging strategy isn't pure NMN/NR supplementation, it's: precursor (NR/NMN) + simultaneous CD38 inhibition.A few research directions:
78c: experimental CD38 inhibitor; in mouse aging models it restores the NAD⁺ pool and improves metabolism (Tarragó 2018 Cell Metab)Apigenin: natural flavonoid in celery / parsley; inhibits CD38 in vitro, but oral doses are far below human-effective levelsLuteolinidin / quercetin: weak in vitro CD38 inhibitors
This is why some researchers hold a mild skepticism toward NMN/NR alone — it's like adding water to a leaky bathtub without patching the leak.
Reality: nobody sells a 'leak-repair solution' on the market because there's no FDA-approved safe human CD38 inhibitor yet. So everything you see at CVS or iHerb is a 'water adder' — precursor-class supplements.
This doesn't mean NMN/NR are completely useless. Short-term raising of the nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. pool is real, and there are some small, limited, surrogate-endpoint signals (next scene). But marketing it as 'reversing aging' doesn't stand mechanistically.
Chapter 3
Marketing arc
Marketing arc
David Sinclair — Harvard geneticist and author of *Lifespan* — is the gravitational center of the NMN/NR market. He's an excellent biologist and also an excellent marketer, and the overlap of those two identities generates a lot of confusion.
At several key moments, the academic signal and the commercial narrative don't align — going point by point:
1. NMN rejuvenates mice?
Mills 2016 Cell Metab: mice given oral NMN 300 mg/kg daily for 12 monthsAging markers improved, insulin sensitivity rose, body weight maintainedNot rejuvenation, not significant lifespan extension (the study design wasn't powered for that)Media translation: 'Harvard scientists discover longevity molecule'Mouse dose translated to a 75 kg human ≈ 1800 mg/day — far above most commercial NMN doses
2. Sirtuins = longevity genes?
Early yeast SIR2 / worm sir-2 experiments showed caloric restriction activates Sirtuins → extends lifespanFollow-up replication studies (Burnett 2011 Nature) substantially weakened the effect, with several original papers receiving correctionsThe 'Sirtuin hypothesis' has been downgraded in scientific circles, but the commercial narrative continues using it
3. Joe Rogan / Andrew Huberman push
Joe Rogan 2019 podcast long-interview with Sinclair → overnight Tru Niagen / various NMN brands surged in salesAndrew Huberman subsequently recommended NRThis is the template of supplement marketing in the podcast era: one celebrity scientist + one celebrity host = millions of orders
4. Sinclair's personal interest conflicts
Founded Sirtris (acquired by GSK for $720M, later failed)Founded Life Biosciences / MetroBiotech (NMN commercial development)These relationships aren't violations, but should be known before purchase decisions
Worth remembering: 'Harvard's David Sinclair recommends it' isn't clinical evidence; it's name recognition, not an evidence base.
At several key moments, the academic signal and the commercial narrative don't align — going point by point:
1. NMN rejuvenates mice?
Mills 2016 Cell Metab: mice given oral NMN 300 mg/kg daily for 12 monthsAging markers improved, insulin sensitivity rose, body weight maintainedNot rejuvenation, not significant lifespan extension (the study design wasn't powered for that)Media translation: 'Harvard scientists discover longevity molecule'Mouse dose translated to a 75 kg human ≈ 1800 mg/day — far above most commercial NMN doses
2. Sirtuins = longevity genes?
Early yeast SIR2 / worm sir-2 experiments showed caloric restriction activates Sirtuins → extends lifespanFollow-up replication studies (Burnett 2011 Nature) substantially weakened the effect, with several original papers receiving correctionsThe 'Sirtuin hypothesis' has been downgraded in scientific circles, but the commercial narrative continues using it
3. Joe Rogan / Andrew Huberman push
Joe Rogan 2019 podcast long-interview with Sinclair → overnight Tru Niagen / various NMN brands surged in salesAndrew Huberman subsequently recommended NRThis is the template of supplement marketing in the podcast era: one celebrity scientist + one celebrity host = millions of orders
4. Sinclair's personal interest conflicts
Founded Sirtris (acquired by GSK for $720M, later failed)Founded Life Biosciences / MetroBiotech (NMN commercial development)These relationships aren't violations, but should be known before purchase decisions
Worth remembering: 'Harvard's David Sinclair recommends it' isn't clinical evidence; it's name recognition, not an evidence base.
四个节点 · 学术信号 vs 商业叙事
几个关键节点上, 学术信号和商业化叙事并不一致, 逐条比对一下:1. 老鼠 NMN 返老还童?
Mills 2016 Cell Metab: 老鼠每天口服 NMN 300 mg/kg, 持续 12 个月老化标记改善, 胰岛素敏感性提升, 体重维持不是返老还童, 不是寿命显著延长 (实验设计也不为此)媒体翻译: 哈佛科学家发现长寿分子老鼠剂量换算到 75 kg 人 ≈ 每天 1800 mg —— 远超大多数商业 NMN 剂量
2. Sirtuins = 长寿基因?
早期酵母 SIR2 / 蠕虫 sir-2 实验显示卡路里限制激活 Sirtuin → 延寿后续重复研究 (Burnett 2011 Nature) 大幅削弱效应, 部分原始论文被勘误Sirtuin 假说在科学界已经被降级, 但商业叙事还在用
3. Joe Rogan / Andrew Huberman 推动
Joe Rogan 2019 podcast 与 Sinclair 长访谈 → 一夜之间 Tru Niagen / 各种 NMN 牌子销量暴涨Andrew Huberman 后续推荐 NR这是 podcast 时代营养营销的范本: 一个明星科学家 + 一个明星主持人 = 几百万订单
4. Sinclair 个人利益相关
创办 Sirtris (后被 GSK 7.2 亿美元收购, 后失败)创办 Life Biosciences / MetroBiotech (NMN 商业开发)这些利益关系没有违规, 但购买决定前应当知情
第一条尤其值得停一下: 剂量换算这一步在传播里几乎总是被跳过。老鼠身上有效的那个量, 折到人身上是商业剂量的好几倍——也就是说, 即便老鼠那套结论原样成立, 你手里那瓶也未必在同一个量级上。机制说得通、动物做出来了、你吃的剂量对得上是三件独立的事, 缺一件, 整条推理就断了。
Brand wars
Main players on the market:NR camp:
Tru Niagen / ChromaDex — the only NR product with FDA NDI (New Dietary Ingredient) acknowledgment, $30–40/month (300 mg)Several NR generic brands
NMN camp:
Wonderfeel — Sinclair-advised, $50–90/monthRenue / ProHealth / DoNotAge — $40–70/monthChinese white-label imports in volume (NMN production cost in China is now very low, ~$200/kg bulk), but purity varies widely
Quality risks:
2022 NSF audits found some NMN products contained less than 50% of label claimNMN is unstable at room temperature, degrading quickly with moisture / lightFDA 2022 issued a warning letter: NMN, because of an active drug trial (Metro Biotech's MIB-626) under review, no longer qualifies as a dietary supplement under the law — but enforcement hasn't followed and the market keeps running
You may not be buying what you think you're buying: this rule always applies, and applies especially in 'fashionable mechanism + ambiguous regulation' lanes.
In contrast, niacin (NA) is FDA-regulated, dose-stable, and 10× cheaper — and it goes through Preiss-Handler to ultimately raise the same nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. pool.
Chapter 4
Clinical RCTs
Clinical RCTs
Real status of human NMN/NR RCTs — and a wide gulf between this and 'reversing aging':
Martens 2018 Nat Commun (NR, n=24, healthy 55–79 years)
1000 mg/day NR × 6 weeks, double-blind crossoverBlood NAD⁺ +60% ✓ (mechanism level holds)Systolic BP −10 mmHg — but only in the hypertensive subgroup; primary analysis had no significant differenceExercise performance / lipids / inflammatory markers / insulin sensitivity: no difference
Yoshino 2021 Science (NMN, n=25, postmenopausal pre-diabetic women)
250 mg/day NMN × 10 weeks, double-blindMuscle insulin sensitivity +25% (P=0.048) ✓Whole-body insulin sensitivity / body fat / lipids / BP / cardiopulmonary function: no differenceSmall sample size, single endpoint significant
Igarashi 2022 (NMN, n=42, elderly men)
250 mg/day × 12 weeksModest gait speed / grip strength improvementNo mortality / cognitive / cardiovascular hard endpoints
Conze 2019 Sci Rep (NR, n=140 healthy overweight adults)
100–1000 mg/day × 8 weeks, safety + pharmacokineticsGood safety ✓No metabolic / performance endpoint improvement
No human RCT currently shows NMN/NR:
Extends lifespan ✗Prevents cancer / cardiovascular events / dementia ✗Meaningfully improves performance / strength / cognition ✗
What there is: raising the nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. pool (mechanism ✓) + a few small signals on surrogate endpoints (B-level evidence).
This is C-grade → B-grade evidence, not A-grade. The marketing rhetoric uses 'mechanism persuasion + mouse success + Harvard endorsement', not hard-endpoint RCTs.
Martens 2018 Nat Commun (NR, n=24, healthy 55–79 years)
1000 mg/day NR × 6 weeks, double-blind crossoverBlood NAD⁺ +60% ✓ (mechanism level holds)Systolic BP −10 mmHg — but only in the hypertensive subgroup; primary analysis had no significant differenceExercise performance / lipids / inflammatory markers / insulin sensitivity: no difference
Yoshino 2021 Science (NMN, n=25, postmenopausal pre-diabetic women)
250 mg/day NMN × 10 weeks, double-blindMuscle insulin sensitivity +25% (P=0.048) ✓Whole-body insulin sensitivity / body fat / lipids / BP / cardiopulmonary function: no differenceSmall sample size, single endpoint significant
Igarashi 2022 (NMN, n=42, elderly men)
250 mg/day × 12 weeksModest gait speed / grip strength improvementNo mortality / cognitive / cardiovascular hard endpoints
Conze 2019 Sci Rep (NR, n=140 healthy overweight adults)
100–1000 mg/day × 8 weeks, safety + pharmacokineticsGood safety ✓No metabolic / performance endpoint improvement
No human RCT currently shows NMN/NR:
Extends lifespan ✗Prevents cancer / cardiovascular events / dementia ✗Meaningfully improves performance / strength / cognition ✗
What there is: raising the nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. pool (mechanism ✓) + a few small signals on surrogate endpoints (B-level evidence).
This is C-grade → B-grade evidence, not A-grade. The marketing rhetoric uses 'mechanism persuasion + mouse success + Harvard endorsement', not hard-endpoint RCTs.
四项试验 · 逐条读
人体 NMN/NR RCT 的真实状态——读的时候留意每项试验后面那串无差异, 它比前面那个 ✓ 更能说明问题:Martens 2018 Nat Commun (NR, n=24, 健康 55-79 岁)
1000 mg/天 NR × 6 周, 双盲交叉血液 nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. +60% ✓ (机制层面成立)收缩压 -10 mmHg —— 但只在高血压亚组, 主分析无显著差异运动表现、血脂、炎症标记、胰岛素敏感性: 无差异
Yoshino 2021 Science (NMN, n=25, 绝经后糖尿病前期女性)
250 mg/天 NMN × 10 周, 双盲肌肉胰岛素敏感性 +25% (P=0.048) ✓全身胰岛素敏感性、体脂、血脂、血压、心肺功能: 无差异样本量小, 终点单一显著
Igarashi 2022 (NMN, n=42, 老年男性)
250 mg/天 × 12 周行走速度、握力小幅改善没有死亡率、认知、心血管硬终点
Conze 2019 Sci Rep (NR, n=140 健康超重成年人)
100-1000 mg/天 × 8 周, 安全性 + 药代安全性良好 ✓没有任何代谢/表现终点改善
把四项并排看, 有两处值得注意。一是阳性信号都出现在亚组或单一指标上: 降压只在高血压那一组成立, 主分析是平的; 肌肉胰岛素敏感性显著而全身的不显著。二是样本都在几十人量级, 这种规模本来就只够看 surrogate 终点, 看不了硬终点——所以没测出来和测出来没有是两回事, 目前的证据只支持前者。这也正是机制成立和对你有用之间那道沟的宽度。
Why no large hard-endpoint trial
Why no large RCT? This itself is worth thinking about:1. Endpoints are too far away
Lifespan endpoint needs 10–20 years of follow-up + n in the thousandsCardiovascular hard endpoint needs n in thousands + 3–5 yearsThis scale of RCT is beyond a single company ($50–200M each)
2. Nobody will run this trial
On the FDA path, NMN is a supplement not a drug → manufacturers have no motive to run hard-endpoint trialsAcademic-led would need NIH / Wellcome funding → no large grant yetThe only one running is Metro Biotech's MIB-626 (drug path); if it succeeds, NMN stops being a supplement
3. Compare with drugs:
Statins: dozens of cardiovascular hard-endpoint RCTs, n=100,000+, all-cause mortality −10–20%Metformin (TAME trial): 6000+ elderly lifespan endpoint, still ongoingNMN/NR: none
So when reading NMN/NR claims, understand:
'Blood nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. +60%' is a mechanistic signal, not a health endpoint'Elderly mouse improvement' is a preclinical signal, not human evidence'David Sinclair takes it daily himself' is an anecdote / signal, not an RCT
None of this means it must be ineffective — it just means the current evidence level doesn't match the marketing intensity. This lane is worth tracking, but not worth all-in betting.
Chapter 5
Decision + niacin trump
Decision + niacin trump
The most counterintuitive fact: same nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. pool — niacin (NA) via Preiss-Handler and NR / NMN via salvage both fill it. But prices differ 10×.
Monthly price comparison (effective doses):
Decision tree:
Q1 What's your goal?
'Longevity / anti-aging / dementia prevention' → no human hard-endpoint evidence, not priority; spend money on sleep / exercise / nutrition / weight / not smoking for far higher ROI'Lipid improvement' → Niacin 2–3 g is FDA-approved prescription / OTC, A-level evidence. But has flushing / liver toxicity; prescriber guidance needed'Insulin resistance / pre-diabetes' → metformin (Rx, A) > weight management / exercise (A) > Berberine (B) > NMN (Yoshino 2021 B-grade, single endpoint)'Just want to try raising NAD⁺' → niacin 500 mg × 2 is cheapest; NR is mid-tier; NMN has the highest marketing premium
Q2 What risk can you tolerate?
Niacin: flushing (90% on first use, develops tolerance), liver toxicity (large doses), blood-sugar disturbanceNR / NMN: good short-term safety data (Conze 2019), long-term unknown
Q3 What do you trust?
FDA-regulated prescription drug → niacin (~$8/month)FDA NDI-accepted supplement → NR / Tru Niagen ($30–40/month)Ambiguous legal status but 'fashionable mechanism' → NMN ($60–90/month)
Worth remembering: when a marketing narrative tells you 'supplement X reverses aging' while a 10× cheaper old drug (niacin) in the same pathway goes unmentioned — that itself is a marketing-level signal.
Monthly price comparison (effective doses):
| Choice | Dose | Monthly cost | Regulation | Evidence level (NAD⁺ rise) |
|---|---|---|---|---|
| Niacin (CVS) | 500 mg × 2 | $8 | FDA-approved lipid drug | A (clear mechanism) |
| NR (Tru Niagen) | 300 mg | $30–40 | FDA NDI accepted | B (Martens 2018) |
| NMN (Renue/Wonderfeel) | 500 mg | $60–90 | Legal status ambiguous | B (Yoshino 2021) |
Decision tree:
Q1 What's your goal?
'Longevity / anti-aging / dementia prevention' → no human hard-endpoint evidence, not priority; spend money on sleep / exercise / nutrition / weight / not smoking for far higher ROI'Lipid improvement' → Niacin 2–3 g is FDA-approved prescription / OTC, A-level evidence. But has flushing / liver toxicity; prescriber guidance needed'Insulin resistance / pre-diabetes' → metformin (Rx, A) > weight management / exercise (A) > Berberine (B) > NMN (Yoshino 2021 B-grade, single endpoint)'Just want to try raising NAD⁺' → niacin 500 mg × 2 is cheapest; NR is mid-tier; NMN has the highest marketing premium
Q2 What risk can you tolerate?
Niacin: flushing (90% on first use, develops tolerance), liver toxicity (large doses), blood-sugar disturbanceNR / NMN: good short-term safety data (Conze 2019), long-term unknown
Q3 What do you trust?
FDA-regulated prescription drug → niacin (~$8/month)FDA NDI-accepted supplement → NR / Tru Niagen ($30–40/month)Ambiguous legal status but 'fashionable mechanism' → NMN ($60–90/month)
Worth remembering: when a marketing narrative tells you 'supplement X reverses aging' while a 10× cheaper old drug (niacin) in the same pathway goes unmentioned — that itself is a marketing-level signal.
决策表 · 价格 · 监管 · 证据
月价格对比 (有效剂量):| 选择 | 剂量 | 月成本 | 监管 | 证据等级 (NAD⁺ 升高) |
|---|---|---|---|---|
| Niacin (CVS) | 500 mg × 2 | $8 | FDA 批降脂药 | A (机制清楚) |
| NR (Tru Niagen) | 300 mg | $30-40 | FDA NDI 认可 | B (Martens 2018) |
| NMN (Renue/Wonderfeel) | 500 mg | $60-90 | 法律地位含糊 | B (Yoshino 2021) |
决策树:
Q1 你的目标是什么?
延寿、抗衰、防痴呆→ 没人体硬终点证据, 不优先, 把钱花在睡眠、运动、营养、体重、不吸烟 上性价比高得多血脂改善→ Niacin 2-3 g 是 FDA 批的处方/OTC, A 级证据。但有 flushing / 肝毒, 处方医生指导胰岛素抵抗、糖尿病前期→ 二甲双胍 (处方, A) > 体重管理、运动 (A) > Berberine (B) > NMN (Yoshino 2021 B 级, 单一终点)就想试试看抬 NAD⁺→ Niacin 500 mg ×2 是最便宜的选项; NR 是中间档; NMN 是营销溢价最高的
Q2 你能承受什么风险?
Niacin: 流脸 (90% 第一次, 慢慢耐受), 肝毒 (大剂量), 血糖紊乱NR / NMN: 短期安全数据良好 (Conze 2019), 长期未知
Q3 你信任什么?
FDA 监管的处方药 → Niacin (~$8/月)FDA NDI 认可的补剂 → NR / Tru Niagen ($30-40/月)法律地位含糊但机制时髦→ NMN ($60-90/月)
读这张表时注意一件事: 证据等级那一列比的是能不能把 nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. 抬起来, 不是能不能让你更健康。三条路在这一列上其实都过得去——差别在价钱和监管身份。真正没有任何一条能填的, 是硬终点**那一列, 而那一列在这张表里根本不存在。
5 should-skip groups + NAD test reading
5 groups that shouldn't supplement NMN/NR:1. Tight budget: the same money spent on sleep + nutrition + exercise gear has 100× the ROI
2. Under cancer screening / chemotherapy / radiation: nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. is a central tumor-metabolism substrate, may promote tumor growth (a real mechanistic risk); your oncologist hasn't told you 'you must supplement'
3. Chronic inflammation / autoimmune disease: PARP / CD38 elevation moves with inflammation, supplementing precursors may amplify certain pathways; data unclear
4. Pregnant / lactating: no human data, skip
5. Thinking 'anti-aging' while still staying up late + not exercising + smoking + sitting all day: your bottleneck isn't NAD⁺
On NAD⁺ blood tests:
Jinfiniti / NAD Quest / Tru Niagen etc. sell $200–500 blood NAD⁺ testsReal data? Partially real: NAD⁺ levels differ widely across tissues (liver / muscle / brain); blood NAD⁺ doesn't fully reflect tissue levelsTests low: doesn't necessarily mean you need NMN/NR; could be high CD38 / chronic inflammation / sleep deprivationTests high: doesn't necessarily mean 'anti-aging success'; could be tissue pool depletion (pathological state)In most cases, these tests are carefully designed marketing funnels — test low → you need to supplement → keep testing → keep paying
The cheapest reliable 'test': your sleep quality, morning energy, exercise recovery speed, and HRV — these reflect overall mitochondrial state and indirectly NAD⁺ utilization. Improving these is more useful than measuring NAD⁺.
References · 5
- Rajman, L., Chwalek, K., & Sinclair, D. A. (2018). Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabolism, 27(3), 529-547. 10.1016/j.cmet.2018.02.011
- Camacho-Pereira, J., Tarragó, M. G., Chini, C. C. S., et al. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through a SIRT3-dependent mechanism. Cell Metabolism, 23(6), 1127-1139. 10.1016/j.cmet.2016.05.006
- Martens, C. R., Denman, B. A., Mazzo, M. R., et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9(1), 1286. 10.1038/s41467-018-03421-7
- Yoshino, M., Yoshino, J., Kayser, B. D., et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224-1229. 10.1126/science.abe9985
- Conze, D., Brenner, C., & Kruger, C. L. (2019). Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports, 9, 9772. 10.1038/s41598-019-46120-z